Innate Pharma strengthens management team

Stephane Boissel, ex-Lazard and PwC, named CFO with responsibility for corporate and business development

Marseille, February 28th, 2003. - Innate Pharma, developer of novel anti-tumoral therapies, announces today the appointment of Stéphane Boissel, 35, as Chief Financial Officer. Boissel's responsibilities will also cover Corporate Development (mergers and acquisitions) and Business Development (in-licensing and out-licensing).
Prior to joining Innate Pharma, Boissel spent more than seven years with Groupe Lazard, in its French and international offices (Singapore and Hong Kong). He started up the technology investment activities of Eurazeo, a member of the Lazard group, in 1995. He was in charge of Lazard's technology fund in Asia before joining the group's Asian M&A department as head of technology activities till January 2002. Back in France, he was director of investments at Eurazeo until August 2002. Before joining Lazard, Boissel spent four years as auditor and consultant in PwC in Paris.
Boissel has an MBA from the University of Chicago. He has a number of French university and professional qualifications including an MSG and DEA from Lyon and Paris-Dauphine and DESCF (accounting) and SFAF (financial analyst).
"The appointment of Stéphane Boissel is a further step in Innate's development coming as it does after the highly successful fund raising last year," said Hervé Brailly, CEO of Innate Pharma. "His international experience and skills in various financial roles mean we can confidently meet the challenges involved in the next stages of Innate's development.",About Innate Pharma :,Innate Pharma S.A.S. 'The Innate Immunity Company', is a French biotechnology company developing immuno-modulating medications and cellular therapies based on the novel concept of 'innate immunity' - stimulation of non-conventional lymphocytes. The main field of research is cancerology, with the first clinical trials begun in 2002. The company was founded in 1999 by a group of four European scientists and two managers from the biotech industry. Companies investing in Innate are Sofinnova Partners, Auriga, GIMV, INSERM Transfert, Alta Partners, Axa Private Equity, Gilde Biotech and Nutrition, Pechel Industries and Innoveris.
Media and analyst contacts:,Andrew Lloyd & Associates - Gilles Petitot - Guillaume Zeller, [phone] - e-mail: [e-mail] - e-mail: [e-mail]

Países

France